Arrowhead Pharmaceuticals Inc at Jefferies Healthcare Conference Transcript
Hi, Everyone. My name is Maury Raycroft, and I'm one of the biotech analysts at Jefferies. I'm happy to welcome our guests Vince Anzalone, Head of IR; and James Hamilton, Chief Discovery and Translational Medicine of Arrowhead. This is going to be a fireside chat format. So maybe to start off, if you guys want to provide a brief intro to Arrowhead.
Sure. Thanks, Mark, and thanks to the whole Jefferies team for having us today. So, Arrowhead is an RNAi therapeutics platform company. So, we have a proprietary technology platform called TRiM or targeted RNA molecules. It allows us to induce target gene silencing across multiple tissue types, including liver, lung, muscle, CNS, and emerging adipose. Right now, we have 12 clinical stage candidates, 7 of those are wholly owned, 5 are partnered. And we have a 20 in '25 initiative, where we want to grow our pipeline of both clinical stage and marketed products to 20 by the year 2025.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |